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Property Protection from U.S. Law
through NAFTA.
Charles Vorndran*
The transition of the U.S. economy from an industrial base to a high technology base
shifts the focus of global competitiveness from the availability of natural resources to the
international protection of intellectual property rights.' The North America Free Trade
Agreement2 (NAFTA) between the United States, Mexico, and Canada specifically addresses
and increases intellectual property protection.3 Moreover, the protection of intellectual prop-
erty rights under the NAFTA will assist U.S. companies dependent on intellectual property
rights to maintain their competitive edge.4
This comment focuses on intellectual property as it applies to the biotechnology industry,
specifically patent protection. First, Part I includes a discussion of what intellectual property
and biotechnology are and how biotechnology relates to the pharmaceutical industry, provid-
ing a foundation for following sections. Because of the importance biotechnology is expected
to have on international trade, Part II covers generally U.S. patent law concerning biotechnolo-
gy. Part III examines in detail patent protections under the NAFTA. Part IV discusses the con-
troversy between developing countries and intellectual property protection. Part V concludes
that the NAFIA has not dramatically changed substantive patent protection and that addition-
al harmonization of domestic laws is needed to adequately protect biotechnology inventions.
* J.D., Southern Methodist University, Class of 1997; Comments Editor, International Law
Review Association of SMU.
1. Bruce A. Lehman, Intellectual Property: America's Competitive Advantage in the 21st Century, 31
COLuM. J. WORLD Bus. 6, 15 (1996). The development of new technologies has transformed the
U.S. economy into one based on ideas and the implementation of these ideas and U.S.
economic growth and competitiveness will largely be determined by the extent to which
the United States creates, owns, preserves and protects its intellectual property, and the
extent to which the federal government can foster economic growth by creating incen-
tives for private sector investment in research and development, promoting stronger
intellectual property protection abroad, reducing barriers to trade and serving U.S. busi-
ness interests throughout the world. Id. at 7.
Additionally, in 1993 a columnist for the Washington Business Journal advised a way to stay in
front of the global pack was "getting more people than our principal competitors out of hog farm-
ing and broom making and into higher value arenas such as computers, aerospace, financial ser-
vices, media and biotech." The Way To Stay in Front of the Global Pack, WASH. Bus. J., Oct. 1, 1993,
available in 1993 WL 5818809.
2. North American Free Trade Agreement, drafted Aug. 12, 1992, revised Sept. 6, 1992, U.S.-Can.-
Mex, 32 I.L.M. 605 (entered into force Jan. 1, 1994) [hereinafter "NAFA"].
3. The North American Free Trade Agreement Implementation Act Statement as to How the NAFTA
Serves the Interests of United States Commerce, available in 1993 WL 561219.
4. Id.
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I. Intellectual Property, Biotechnology, and the Pharmaceutical
Industry.
A. SCOPE OF INTELLECTUAL PROPERTY.
Intellectual property includes primarily copyrights, trademarks, patents, service
marks, and trade secrets.5 This broad term is also used to describe the many "rights associ-
ated with inventions, discoveries, writings, artistic works, product designs, and designa-
tions of the source of goods and services."6 The importance of the protection of intellec-
tual property rights is evidenced by the many international trade conventions and treaties
ranging from the Paris Convention for the Protection of Industrial Property Rights of
18837 to the NAFTA.8 Some of the industries that rely on the protection of intellectual
property include: "movies, TV programs, home video, books, music, sound recordings,
and computer software."9 Pharmaceutical and biotechnology industries also depend heav-
ily on the protection of intellectual property rights. 10 In fact, "[the biotech] industry
would not exist in America today without strong patent protection' 11 Moreover, "[tihe
future of the pharmaceutical industry hinges largely on the results of the North American
Free Trade Agreement and the General Agreement on Tariffs and Trade." 12
Since 1992 global trade arrangements have significantly increased, demonstrating the
importance of world-wide trade in today's economy. 13 Of the many agreements, the
5. Margaret A. Boulware et al., An Overview of Intellectual Property Rights Abroad, 16 Hous. J. INT'L
L. 441,445 (1994).
6. Rebecca Eisenberg, Patents: Help or Hindrance to Technology Transfer, in BIOTECHNOLOGY SCIENCE,
ENGINEERING, AND ETHICAL CHALLENGES FOR THE TWENTY-FIRST CENTURY 161 (Frederick B.
Rudolph & Larry V. MacIntire eds., 1996).
7. Paris Convention for the Protection of Industrial Property, July 14, 1967, 21 U.S.T. 1538, 828
U.N.T.S. 305.
8. NAFTA, supra note 2. Some other important U.S. treaties include- (1) Patent Cooperation Treaty,
June 19, 1970, 28 U.S.T. 7645; (2) Berne Convention for the Protection of Literary and Artistic
Works, as revised July 24, 1971, 102 Stat. 2853, U.N.T.S. 221; and (3) Universal Copyright
Convention, as revised July 24, 1971, 25 U.S.T. 1341, 943 U.N.T.S. 178. Boulware, supra note 5, at
507 & n.1.
9. Remarks of the Honorable Carlos 1. Moorhead Before the Patent and Trademark Office Society, 78 J.
PAT. [& TRADEMARK] OFF. SOc'Y 225,228 (1996) [hereinafter Moorhead].
10. James Silbermann, Comment, The North American Free Trade Agreement's Effect on
Pharmaceutical Patents: A Bitter Pill to Swallow or a Therapeutic Solution?, 12 J. CONTEMP. HEALTH
L. & POL'Y 607,635 (1996). One commentator has suggested that without patent protection, the
pharmaceutical industry will become a governmental entity which would "erode our capitalist
society into a socialist system where there are no entrepreneurs willing to risk the often enor-
mous costs in terms of time, research, and development if order to bring a new invention to mar-
ket" Id.
11. Moorhead, supra note 9, at 227.
12. Mark Perkies, Bitter Pills: Mergers, Price Cuts, Layoffs the Medicine for Pharmaceutical Companies,
PLANT SITES & PARKS 107, available in 1995 WL 14088934.
13. Ralf Boscheck, Mastering Management - Part 18 (9): Managed Trade and Regional Choice - Ralf
Boscheck Examines Regional Trade Blocs, a Rapidly Growing Phenomemon. Are They, as Many Fear,
Barely Disguised Protectionism or a Step Towards Global Free Trade?, FIN. TIMES, Mar. 8, 1996,
available in 1996 WL 6148707.
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NAFTA is "probably the strongest intellectual property agreement and trade agreement
ever.. -,14 Future implications of the drive toward consensual global regulation of intellec-
tual property on the biotech industry are difficult to predict.15
B. DEPENDENCE OF INDUSTRIES ON INTELLECTUAL PROPERTY PROTECTION.
High-tech industries incur extremely high costs in research and development (R&D),
resulting in the necessity of intensive investment.16 For example, "[iln 1995 the biotech
industry spent $7.7 billion on research and development."'17 Unauthorized copying of
new technologies avoids the investment of R&D, thereby preventing the inventor from
recouping its initial investment. 18 Therefore, the protection of intellectual property pre-
vents unauthorized copying and is the cornerstone of high-tech industries. 19
American businesses lose approximately $200 billion to counterfeiters annually, and
biotechnology and pharmaceuticals are becoming popular targets. 20 It is believed this trend
will continue in the future, despite the danger some counterfeit goods pose to public safety.21
Although stronger protections for intellectual property will help alleviate some of the coun-
terfeiting by making it less profitable, trade agreements alone may not afford adequate pro-
tection.22 In fact, some suggest businesses take proactive steps to avoid counterfeiting, such
as: legitimizing offenders; educating stockholders; advertising, and high-tech labeling.23
14. Hearing Before the Committee on Finance United States Senate, 104th Cong., ist Sess. (1995)
(Statement of Rebecca Maynard, Professor of Education and Social Policy, Univ. Of
Pennsylvania). See also Pharmaceuticals, 4 MEx. TRADE & LAW REP. 24, 26 (1994); Bruce Zagaris &
Alvaro J. Aguilar, Enforcement of Intellectual Property Protection Between Mexico and the United
States: A Precursor of Criminal Enforcement for Western Hemispheric Integration?, 5 FORDHAM
INTELL. PROP. MEDIA. & Err. L.J. 41,107 (1994).
15. Louis Lasagna, Comparison of U.S., European, and Japanese Policies Affecting Pharmaceutical and
Biotechnology Development, in BIOTECHNOLOGY SCIENCE, ENGINEERING, AND ETHICAL CHALLENGES
FOR THE TWENTY-FIRST CENTURY, supra note 6, at 225,227. See also Kenneth D. Sibley, Introduction
to THE LAW AND STRATEGY OF BIOTECHNOLOGY PATENTS 1 (Kenneth D. Sibley ed., 1994)(writing "it
is often felt that the patent system itself, at least in the area of biotechnology, is capricious and
unpredictable.").
16. Lehman, supra note 1, at 10. The author continues by writing "[allthough investment leads to
innovation, to take these ideas form a laboratory or a studio to the marketplace requires a critical
next step, gaining protection for this new intellectual property." Id. at 10-11.
17. Kate H. Murashige, Genome Research and Traditional Intellectual Property Protection-A Bad Fit?, 7
RISK: HEALTm SAFETY & ENV'T 231,232 (1996).
18. Lehman, supra note 1, at 14.
19. Gerald J. Mossinghoff & Thomas Bombelles, The Importance of Intellectual Property Protection to
the American Research Intensive-Pharmaceutical Industry, 31 COLUM. J. WORLD Bus. 38 (1996).
20. Clifford J. Shultz II & Bill Saporito, Protecting Intellectual Property: Strategies and
Recommendations to Deter Counterfeiting and Brand Piracy in Global Markets, 31 COLUM. J.
WORLD Bus. 18, 19 (1996).
21. Id.
22. Id. at 26.
23. Id. at 22-26.
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C. MERGING OF PHARMACEUTICAL AND BIOTECHNOLOGY INDUSTRIES.
The pharmaceutical industry has become one of the most competitive and successful
high-technology industries in the United States.24 In 1994 this industry had a trade surplus of
exported US $525 million.25 As a result, U.S. pharmaceutical industries are very concerned
with the global harmonization of intellectual property protection.26 Because of the limited
availability of new drugs coming directly out of nature and the rapid advancement in the area
of biotechnology, many of the large pharmaceutical firms are turning to biotechnology to help
identify new drugs. 27 By September 1996 sixteen biotechnology based pharmaceuticals had
been approved by the Food and Drug Administration (FDA) for that year.28
The U.S. biotech industry has grown tremendously in the last fifteen years.29 In fact, the
industry has blossomed into one producing almost $8 billion in revenues in the United
States and creating 103,000 new jobs.30 Moreover, global markets for biotechnology based
products are expected to grow to US $30-$50 billion per year in the next ten years.31 As a
result, biotechnology and the biotech industry are expected to have a great impact on inter-
national trade.32
24. Prepared Testimony of Robert Neimeth Charirman, Intellectual Property Task Force International
Section Pharmaceutical Research and Manufacturers of America and President, International
Pharmaceuticals Group Pfizer, Inc. Before the Committee on Ways and Means Subcommittee on
Trade and the Committee on Rules Subcommittee on Rules and Organization United States House of
Representatives Keeping Trade with Latin America on the Fast Track, Fed. News Service - Cong.
Hearings Testimonies, May 17, 1995, available in 1995 WL 10386192.
25. Id.
26. Bruce Rubenstein, Latin America Slow to Protect Patents under NAFTA, 6 CORP. LEGAL TIMES 14
(1996).
27. Philip H. Abelson, Pharmaceuticals Based on Biotechnology, 273 SCIENCE 719 (1996)
(Approximately 170 collaborative arrangements between pharmaceutical and biotech companies
were established in 1995). However, at least one new company, Vertex Pharmaceuticals, has
adopted the "rational" approach to developing new drugs. The Pizzaz Factor (U.S. business sys-
tem)(A Survey of American Business: Back on Top), ECONOMIST, Sept. 16, 1995, Vol. 336, avail-
able in 1995 WL 9570600. The rational approach attempts to design new drugs chemically rather
than testing them by trial and error. Id.
28. Ableson, supra note 27, at 719. "[lthe U.S. Food and Drug Administration is receiving more new
drug applications from the biotech industry than from big pharmaceutical companies." Jennifer
Lanthier, Visionary With Clout. Ed Rygiel Thinks Biotech Can Make Canada and the World a Better
Place, and as MDS Health Group's Venture Capital Guru, He's in a Position to Help Make it
Happen, FIN. POST, Sept. 17, 1996, at 62.
29. Moorhead, supra note 9, at 226. Biotechnology has been heralded as "one of the most significant
developments of this century." Lanthier, supra note 28 (quoting Ed Rygiel, vice-president of cor-
porate development with MDS Health Group Ltd.).
30. Moorhead, supra note 9, at 226 (stating the biotech industry "has created more nutritious foods
and vital medical treatments for cancer and heart patients than all other research industries com-
bined. And, it's almost exclusively, an American industry." Id.).
31. NATURAL RESOURCE COUNCIL, PUTTING BIcrTECHNOLOGY TO WORK, BIOPROCESS ENGINEERING, 9, 10
(1992) (hereinafter Natural].
32. Gerd Junne, The Impact of Biotechnology on International Trade, in BIOTECHNOLOGY- ECONOMIC AND
SOCIAL ASPECTS, ISsUES FOR DEVELOPING COUNTRIEs, 165, 185 (E. J. Da Silva et al. eds., 1992)(predict-
ing "[tihe impact of biotechnology on trade flows is hard to measure.' Moreover, "[a]pplications of
biotechnology will first of all affect [international] trade in agricultural products." IdM).
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D. DEFINING BIOTECHNOLOGY.
Biotechnology means different things to different people.33 The National Resource
Council defines biotechnology as "the application of science and engineering to the use of
living organisms or substances derived from them, to generate products or to perform func-
tions that can benefit the human condition."34 Biotechnology, therefore, is not a science in
itself, rather, it is the application of science used to either make money or to save it.35
Biotechnology as a business begins with the successful translation of basic research in
the life sciences into very high-value-added products, including biopharmaceuticals for the
treatment of diseases such as heart disease, cancer, and kidney diseases. 36 In so doing, the
distinction between biotechnology and pharmaceuticals begins to blur. Pharmaceutical
products now include those derived from biotechnology, giving birth to the term biophar-
maceutical. 37 Some biopharmaceuticals are products of new recombinant deoxyribonu-
cleic acid (DNA) 38 and hybridoma technology,39 vaccines, and therapeutic proteins. 40
These "[bliotechnology-derived products are an important source of revenue and com-
mercial growth throughout the world and hence are related to issues of international com-
petitiveness."41
An additional reason pharmaceutical industries and biotech industries are combining
forces is the interest the pharmaceutical industry has in using biological synthesis of prod-
ucts rather than traditional chemical synthesis. 42 Chemical synthesis typically results in a
mixture of product.43 The mixture contains enantiomers, left and right-handed versions
33. Colin Ratledge, Biotechnology: The Socio-economic Revolution? A Synoptic View of the World Status
of Biotechnology, in BIOTECHNOLOGY: ECONOMIC AND SOCIAL ASPECTS, ISSUES FOR DEVELOPING
COUNTRIES, supra note 32, at 1. The author traces the practice of biotechnology techniques from
the first production of wines to the advent of recombinant DNA technology and concludes both
the traditionalist view and the modem view of biotechnology are interdependent. Id.
34. Natural, supra note 31, at 9.
35. Ratledge, supra note 33, at 1. A more descriptive definition of biotechnology is a collection of
scientific techniques applicable to several industries. TREVOR COOK ET AL., PHARMACEUTICALS
BIOTECHNOLOGY AND THE LAW 5 (1991).
36. Natural, supra note 31, at 13.
37. Id. at 16.
38. Recombinant DNA technology is "a laboratory technique used to join deoxyribonucleic acid
from different sources to produce an individual with a novel gene composition." McGRAw-HILL
DICTIONARY OF SCIENTIFIC AND TECHNICAL TERMs 1576 (4th ed. 1989) [hereinafter McGraw-Hill].
39. Hybridoma technology is used for the production of monoclonal antibodies. Cook, supra note
35, at 114. Antibodies are proteins produced by immune cells that bind to sites on foreign agents
(antigens) in the body as part of the immune response. Id. Monoclonal antibodies bind to the
same antigenic site, giving them extreme sensitivity, and can be produced in large quantities. Id.
They have important uses in diagnostics, e.g. home pregnancy tests. Id. Monoclonal antibodies
can also be important in the "targeted delivery of toxic drugs" in the treatment of cancer. Id.
40. Natural, supra note 31, at 16. A protein is "[alny of a class of high molecular weight polymer
compounds composed of a variety of -amino acids joined by peptide linkages.' McGraw-Hill,
supra note 37, at 1510. Amino acids are the building blocks of proteins. Id. at 74.
41. Natural, supra note 31, at 38.
42. Michael Shuler, Development of Biopharmaceuticals: An Engineering Perspective, in
BIOTECHNOLOGY SCIENCE, ENGINEERING, AND ETHICAL CHALLENGES FOR THE TWENTY-FIRST
CENTURY, supra note 6, at 100, 106.
43. Id.
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of the same molecule; hopefully one enantiomer will have the desired effect and the other
will have no effect.44 Occasionally, however, one of the enantiomers can have harmful
effects.45 The advantage of biological synthesis is that only the beneficial enantiomer is
produced, thereby avoiding contamination of the product with deleterious enantiomers. 46
Finally, pharmaceutical firms are entering the biotech industry because many of the
molecules that produce physiological responses useful in the treatment of disease are not
simple chemicals. 47 Rather, these molecules are often complex proteins or fragments of
proteins that require complex chemistry to synthesize, and the yield of the synthesis is
often very low.48 Biotechnology can use nature's own machinery to produce these com-
plex molecules in sufficient quantities to make the product economically profitable.49
When thinking of biotechnology, most people quickly begin to imagine genetics and
DNA.50 The development of technology allowing the manipulation of genes to produce
designed changes in living organisms has resulted in the production of several products
used to treat human disease.51 For example, insulin,52 human growth hormone,53 and
erythropoietin 54 can now be produced in bacteria or yeast and can be used to treat
humans. 55 The key to the successful production of a therapeutic protein is making sure
the recombinant protein is modified in the same manner in bacteria as it would be in
humans. Simply knowing the genetic code of the protein may not be sufficient to produce
a marketable product.
Other products of biotechnology include genetically engineered animals and plants. 56
Genetically engineered (transgenic) animals can be used in the research and development




47. Cook, supra note 35, at 7.
48. Id.
49. Id.
50. See generally Anita Varma & David Abraham, DNA is Different Legal Obviousness and the Balance
Between Biotech Inventors and the Market, 9 HARV. J.L. & TECH. 53 (1996) and Murashige, supra
note 17.
51. Teresa Pechulis Buono, Note, Biotechnology-Derived Pharmaceuticals: Harmonizing Regional
Regulations, 18 SUFFOLK TRANSNAT'L L REV. 133, 137 (1995).
52. Natural, supra note 31, at 14. Recombinant insulin became rapidly available after the discovery of
Type II restriction endonucleases, enzymes used to cut DNA. Id.
53. Murashige, supra note 17, at 231.
54. Id.
55. Shuler, supra note 42, at 101. Once the protein is formed it may undergo some of the following
modifications to produce a functional protein: folding, addition of sugars, disulfide bond forma-
tion, and the addition of phosphate groups. Id
56. See generally Elisabeth T. Jozwiak, Comment, Worms, Mice, Cows and Pigs: The Importance of
Animal Patents in Developing Countries, 14 Nw. J. INT'L L. & Bus. 620; Mark Hanning, An
Examination of the Possibility to Secure Intellectual Property Rights for Plant Genetic Resources
Developed by Indigenous Peoples of the NAFTA States: Domestic Legislation Under the International
Convention for the Protection of New Plant Varieties, 13 ARIZ. J. INT'L & COMp. L. 175 (1996).
57. Jozwiak, supra note 56, at 623. Transgenic animals can be used to produce vaccines or to test
available drugs for effectiveness. Id.
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more food than unaltered animals or can be designed to grow faster on lower levels of
nutrition.58 With increasing demand for food production, these animals may be impor-
tant in preventing starvation.
59
II. U.S. Patent Law and Biotechnology.
A. SUBJECT MATTER.
In the United States, the patent statute is found in Title 35 of the U.S. Code.60 Section
101 provides "[w]hoever invents or discovers any new and useful process, machine, manu-
facture, or composition of matter, or any new and useful improvement thereof, may obtain
a patent therefor, subject to the conditions and requirements of this tide."6 1 The courts
have interpreted this language as requiring three elements necessary for an invention to be
patentable: (1) novelty; (2) utility; and (3) statutory subject matter.62 The requirement for
statutory subject matter means an invention must fall within one of the enumerated cate-
gories listed in the statute.63 Because biotechnological inventions by definition are con-
cerned with living matter and nature, the patentability of biotechnological products must
fall in the composition of matter or process elements of the statute.64 Generally, patent
applications contain claims that reflect the subject matter of the invention.65
Despite the seemingly narrow scope of patentable subject matter, the U.S. Supreme
Court determined Congress' intent was that "anything under the sun that is made by man"
is patentable subject matter. Still, the product of nature doctrine serves as "a limitation on
patentable subject matter," but it does not distinguish between "'animate and inanimate
naturally occurring products." 67
58. Id.
59. Id.
60. The sections of the statute discussed in this comment are 35 U.S.C. §§ 101-104 (1994). The
patent statute was originally enacted in 1952.
61. 35U.S.C.§ 101.
62. In re Bergy, 596 F.2d 952, 960 (C.C.P.A. 1979). See also Boulware, supra note 5, at 465; Robert
Patrick Merges, PAT.L.& POL'Y 147 (1992) (writing the three requirements are novelty, utility and
non-obviousness).
63. Brian P. O'Shaughnessy, Patentable Subject Matter, in THE LAW AND STRATEGY OF BIOTECHNOLOGY
PATENTS, supra note 15, at 62 citing In re Pardo, 684 F.2d 912,916 (C.C.P.A. 1982)("[a]ny process,
machine, or composition of matter constitutes statutory subject matter unless it falls within a
judicially determined exception to section 101.').
64. But see id. at 62, writing that '[the four [statutory] categories are somewhat ambiguous" and
determining "whether a genetically altered cell that manufactures recombinant human proteins is
a machine or composition of matter" is an issue on which reasonable minds may differ. Id.
65. Stephen G. Whiteside, Note, Patents Claiming Genetically Engineered Inventions: A Few Thoughts
on Obtaining Broad Property Rights, 30 NEw ENG. L. REV. 1019, 1024 (1996). The claims define the
invention. Id. at 1023.
66. Diamond v. Chakrabarty, 447 U.S. 303,309 (1980).
67. KENNETH J. BuRcHFIEL, BIOTECHNOLOGY AND THE FEDERAL CIRCWrT 41 (1995). The product of
nature doctrine establishes that a product of nature, whether living or not, cannot be the subject
matter of a patent. Id. at 40-41. Additionally, scientific principles and mathematical methods are
not patentable. Boulware, supra note 5, at 459.
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Although a naturally occurring product is typically not patentable, some ways to
secure a patent for such a product may exist.68 The isolation and purification of a natural
product may be patentable by the claims of the patent even if the subject matter is one
occuring in nature.69 A simple but "affirmative manipulative step" can secure a patent on
a natural product under the U.S. patent statute.70
Living organisms were declared patentable in the landmark decision of Diamond v.
Chakrabarty.71 Although a process involving living organisms such as bacteria has generally
been accepted as patentable, the patenting of the living thing itself has spawned controversy.72
In Chakrabarty, the Supreme Court reversed the rejection of a patent application on a
"human-made, genetically engineered bacterium capable of breaking down multiple compo-
nents of crude oil."7 3 The Court held the invention constituted a manufacture or composi-
tion of matter within the meaning of the statute. 74 The recognition of micro-organisms as
patentable subject matter led to the patentability of multicellular organisms. 75 On April 21,
1987, the Patent and Trademark Office (PTO) released a notice recognizing the patentability
of"nonnaturally occurring nonhuman multicellular living organisms' 76 Despite the recog-
nition of multicellular organisms as patentable subject matter, one scholar has suggested the
PTO has effectively imposed a moratorium on patents for higher vertebrates. 77
B. UTILITY.
In addition to being within the statutory subject matter, a biotechnological invention,
as with any invention, must also be useful to secure a patent. 78 Two requirements fall
within the standard of utility: (1) operability and (2) practical utility.79 Operability refers
68. O'Shaughnessy, supra note 63, at 63 citing Ex Parte Prescott, 19 U.S.P.Q. 178 (Bd. Pat. App. 1932)
for the proposition that a patent may be granted for a product of nature if it involves: "(1) isola-
tion or purification to yield products not otherwise useful in their natural state, and (2) the use
of a product in a novel and non-obvious process.' Id.
69. Id. at 64. The claims can define the invention as not being a product of nature. Id.
70. Id. at 65.
71. Chakrabarty, 447 U.S. at 303.
72. O' Shaughnessey, supra note 63, at 65. See also BURCHFIEL, supra note 67, at 42, noting that the
grant of a patent on the "Harvard mouse" resulted in legislative proposals to remove higher ani-
mals from patentable subject matter and legal action against the Commissioner of Patents and
Trademarks.
73. Chakrabarty, 447 U.S. at 305. The invention was to be used in treating oil spills. Id.
74. IdM at 309. "[t]he patentee has produced a new bacterium with markedly different characteristics
from any found in nature and on having the potential for significant utility. His discovery is not
nature's handiwork, but his own; accordingly it is patentable subject matter under § 101." Id.
75. BURCHFIEL, supra note 67, at 41.
76. O'Shaughnessy, supra note 63, at 67.
77. BURCHFIEL, supra note 67, at 43. In 1991 approximately 157 animal patents had not issued. Id.
Recently, a petition was filed with the PTO to "impose a moratorium on the issuance of patents
for living organisms" by Jeremy Rifkin's Foundation for Economic Trends, joined with main-
stream religious leaders. Brian C. Cunningham, Impact of the Human Genome Project at the
Interface Between Patent and FDA Laws, 7 RISK: HEALTH SAFETY & ENV'T 253,262 (1996).
78. 35 U.S.C. § 101.
79. BURCHFIEL, supra note 67, at 47.
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to "whether the invention works' 80 Practical utility is whether the invention is useful. 81
The requirement that an invention be useful does not generally become an issue for
mechanical and electrical inventions, but biotechnological inventions are occasionally
challenged on this basis.82 Since the mid-1960s, the element of practical utility has
spawned controversy.83
In Brenner v. Manson, the U.S. Supreme Court recognized the "everyday word [utility]
can be pregnant with ambiguity when applied to the facts of life."84 The process patent at
issue concerned a chemical process for producing steroids. 85 The patent application did
not include any utility for the compounds produced by the process; however, the applicant
argued the process patent produced a homologue86 to steroids demonstrated to have
tumor-inhibiting effects in mice.8 7 Although the Court recognized the process had some
utility because the process worked and the products could be used for future testing, the
Court held this alone was insufficient to grant a patent 88 The Court reasoned that "until
the process claim has been reduced to production of a product shown to be useful, the
metes and bounds of that monopoly [of knowledge] are not capable of precise delin-
eation."89 As a result, the benefit to the public would not be commensurate with the bene-
fit resulting from the granting of such a broad patent. Because the Court also included
that the "'patent system must be related to the world of commerce rather than the realm of
philosophy.. .,"90 the determination of practical utility encompasses a chemical or chemi-
cal process' commercial applicability. 91
Commercial applicability could present a problem for biotechnology since it generates
many inventions that do not have immediate commercial use but are useful in research. 92 In
fact, the PTO "has frustrated the full realization of patenting pharmaceutical biotechnology
80. O'Shaughnessy, supra note 63 at 71; BURCHFIEL, supra note 67, at 48.
81. O'Shaughnessy, supra note 63, at 69.
82. Boulware, supra note 5,467-68.
83. O'Shaughnessy, supra note 63, at 69.
84. Brenner v. Manson, 383 U.S. 519, 529 (1966).
85. Id. at 520.
86. "A homologous series is a family of chemically related compounds, the composition of which
varies from member to member by CH(2)(one atom of carbon and two atoms of hydrogen)..."
Id. at 522 & n.3 (quoting Application of Henz, 181 F. 2d 196,200-201 (C.C.P.A.)).
87. Id. at 521-22.
88. Id. at 535.
89. Id. at 536.
90. Id. (quoting Application of Ruschig; 343 F. 2d 970 (C.C.P.A.)).
91. BURCHFIEL, supra note 67 at 51. Additionally, this interpretation of the utility requirement was
extended in Application of In re Kirk, 376 F.2d 936, 942 (C.C.PA. 1967)(holding that claims
describing the invention as having biological activity and usable to prepare compounds with bio-
logical properties did not meet the utility requirement). O'Shaughnessy, supra note 63, at 69;
Merges, supra note 62, at 152. It should be noted that claims of inventions in humans may
require clinical trials to establish utility. O'Shaughnessy, supra at 72 (citing Ex parte Balzarini, 21
U.S.P.Q. 2d 1892, 1897 (Bd. Pat. App. 1991)).
92. BURCHFIEL, supra note 67, at 57.
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inventions by rejecting inventions on the grounds that they do not meet the § 101 require-
ment that the invention be 'useful' because they do not recite human clinical in vivo data!'93
A specific example of how the controversy with utility affects the biotechnology
industry is the attempt of the National Institutes of Health to patent expressed sequence
tags.94 Expressed sequence tags are stretches of DNA sequenced from randomly selected
complementary DNAs that correspond to small coding regions of genes without knowing
the function of the genes.95 The argument against the utility of the patent was basically
that the utility of the patent would not be known until the full sequence of the gene and
the structure and function of the proteins the genes encode was known.96 The patent
application was abandoned for fear the grant of the patent would hinder further research
and/or hinder the Human Genome Project. 97
C. NOVELTY.
The novelty requirement is located in 35 U.S.C. § 102.98 The information in section
93. Garth Butterfield et al., Biotechnology Protection and Licensing 431 PLI/PAT 235, 244 (1996). The
PTO has adopted guidelines for establishing a prima facie case of lack of utility. A prima facie
case for no utility must establish that a person skilled in the art would not consider credible any
specific utility asserted by the applicant for the claimed invention. Id. at 244. The following ele-
ments must be included: "(i) [a] well reasoned statement that clearly sets forth the reasoning
used in concluding that the assert utility is not credible; (ii) [slupport for factual findings relied
upon in reaching this conclusion; and (iii) [slupport for any conclusions regarding evidence pro-
vided by the applicant in support of an asserted utility." Id. at 245.
94. BURCHFIEL, supra note 67, at 58; Murashige, supra note 17, at 235-36.
95. BURCHFIEL, supra note 67, at 58.
96. Id
97. Id. "The Human Genome (Project) is an international effort to complete the sequencing of the
100,000 genes that comprise the human genome." Cunningham, supra note 77, at 253.
98. 35 U.S.C.A. § 102 (1984) provides:
A person shall be entitled to a patent unless--
(a) the invention was known or used by others in this country, or patented or
described in a printed publication in this or a foreign country, before the invention
thereof by the applicant for patent, or
(b) the invention was patented or described in a printed publication in this or a foreign
country or in public use or on sale in this country, more than one year prior to the date
of the application for patent in the United States, or
(c) he has abandoned the invention, or
(d) the invention was first patented or caused to be patented, or was the subject of an
inventor's certificate, by the applicant or his legal representatives or assigns in a foreign
country prior to the date of the application for patent in this country on an application
for patent or inventor's certificate filed more than twelve months before the filing of
the application in the United States, or
(e) the invention was described in a patent granted on an application for patent by
another filed in the United States. before the invention thereof by the applicant for
patent, or on an international application by another who has fulfilled the require-
ments of paragraphs (1), (2), and (4) of section 371(c) of this title before the invention
thereof by the applicant for patent, or
(f) he did not himself invent the subject matter sought to be patented, or
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102 has been described as being presented in a "convoluted fashion." 99 Basically, the nov-
elty requirement is meant to ensure the invention described in a patent application has not
been known, used, patented, or described in a publication. 1°° Unlike most other industri-
alized countries, the United States allows a one year grace period to file a patent applica-
tion after public disclosure or sale of the invention. 10 1
If an invention has been publicly disclosed, sold, known, used, or patented more than
a year before filing a patent application, the invention is said to be "anticipated" and is
denied patent protection. 102 The application of the novelty requirement coupled with the
products of nature doctrine poses potential problems for biotechnological inventions.103
The reason some biotechnological inventions may not appear to be novel stems from
the similarity of a genetically engineered product compared to its natural form. For exam-
ple, a recombinant protein is produced to perform the same function as the naturally
occurring protein. Consequently, the recombinant protein closely resembles the structural
and chemical identity of the natural protein.
Despite this high degree of similarity, biotechnology products have been held to be
novel on several different grounds.
First, anticipation can be avoided if the recombinant protein product is of more
increased purity than the unpurified form found in nature. 104 Moreover, as long as one
amino acid of the recombinant protein is different than the natural protein, the recombi-
nant protein will be novel. 105 Second, a biotechnological invention will be novel if it has
increased biological activity over its naturally occurring counterpart. 106 Lastly, artificial
(g) before the applicant's invention thereof the invention was made in this country by
another who had not abandoned, suppressed, or concealed it. In determining priority
of invention there shall be considered not only the respective dates of conception and
reduction to practice of the invention, but also the reasonable diligence of one who
was first to conceive and last to reduce to practice, from a time prior to conception by
the other.
99. James R. Cannon, Novelty and the Public Domain, in THE LAW AND STRATEGY OF B1OTEcHNoLOGY
PATENTS, supra note 15, at 75.
100. 35 U.S.C.A. § 102; Merges, supra note 62, at 162; Boulware, supra note 5, at 465(writing that
"[m]ost countries require absolute novelty," which means there must be no public disclosure or
commercial exploitation of the invention before the patent application is filed). Cannon notes a
one year grace period is useful because it gives the inventor time to investigate the commercial
use of the invention and whether pursuing a patent application is economically justified.
Cannon, supra note 99, at 80.
101. 35 U.S.C.A. § 102(b); Boulware, supra note 5, at 465.
102. Cannon, supra note 99, at 75. For prior art to anticipate an invention, it must: (1) disclose each
element of the claimed invention; (2) be enabling in that a person skilled in the art could make
and use the invention based on the prior art; and (3) not fall within the "'accidental anticipation'
exception" Id. at 76. For an analysis of the accidental anticipation exception see id. at 79.
103. BURCHFIEL, supra note 67, at 60-61.
104. Id. at 65.
105. Id. at 66. The same reasoning can be applied to cloned genes in which the cloned sequence differs
from the naturally occurring sequence. Importantly, this differences must be claimed in the
patent application. Id.
106. Id.
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biological constructs such as plasmids, vectors, and transformed cells do not occur natu-
rally and are, therefore, novel. 107
D. NONOBVIOUSNESS.
In addition to novelty, utility, and statutory subject matter, an invention must not be
obvious to one skilled in the art in order to become patented. 108 The nonobviousness
requirement is premised on the concept that an invention that is "merely a trivial step for-
107. Id.
108. 35 U.S.C.A. § 103 (West Supp. 1996) which provides:
(a) A patent may not be obtained though the invention is not identically disclosed or
described as set forth in section 102 of this title, if the differences between the subject
matter sought to be patented and the prior art are such that the subject matter as a
whole would have been obvious at the time the invention was made to a person having
ordinary skill in the art to which said subject matter pertains.
(b)(1) Notwithstanding subsection (a), and upon timely election by the applicant for
patent to proceed under this subsection, a biotechnological process using or resulting
in a composition of matter that is novel under section 102 and non-obvious under
subsection (a) of this section shall be considered non-obvious if--
(A) claims to the process and the composition of matter are contained in either the
same application for patent or in separate applications having the same effective filing
date; and
(B) the composition of matter, and the process at the time it was invented, were owned
by the same person or subject to an obligation of assignment to the same person.
(2) A patent issued on a process under paragraph (1)--
(A) shall also contain the claims to the composition of matter used in or made by that
process, or
(B) shall, if such composition of matter is claimed in another patent, be set to expire
on the same date as such other patent, notwithstanding section 154.
(3) For purposes of paragraph (1), the term "biotechnological process" means--
(A) a process of genetically altering or otherwise inducing a single- or multi-celled
organism to--
(i) express an exogenous nucleotide sequence,
(ii) inhibit, eliminate, augment, or alter expression of an endogenous nucleotide
sequence, or
(iii) express a specific physiological characteristic not naturally associated with said
organism;
(B) cell fusion procedures yielding a cell line that expresses a specific protein, such as a
monoclonal antibody; and
(C) a method of using a product produced by a process defined by
subparagraph (A) or (B), or a combination of subparagraphs (A) and (B).
(c) Patentability shall not be negatived by the manner in which the invention was
made. Subject matter developed by another person, which qualifies as prior art only
under subsection (f) or (g) of section 102 of this title, shall not preclude patentability
under this section where the subject matter and the claimed invention were, at the time
the invention was made, owned by the same person or subject to an obligation of
assignment to the same person. [See Butterfield, supra note 93, at 256-72 for a detailed
discussion of the relevant case law in the area of biotechnology and the issue of obvi-
ousness.]
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ward in the art" does not contribute enough benefit to the public to justify the issuance of
a patent.109 Determining exactly what is obvious is not a simple matter. 11 0 Moreover, the
requirement of nonobviousness can present more problems for biotechnology inventions
than other types of inventions because rejections of biotechnology based patent applica-
tions are based on both obviousness and the lack of enablement. 11 Defending the applica-
tion against obviousness may result in conceding the lack of enablement because of the
complexity of the techniques involved.112
After the enactment of section 103, an invention is not required to demonstrate a
"flash of creative genius"1 3 Rather, the statute sets out a test that has been interpreted as
having the following elements: (1) determination of the scope and content of the prior art;
(2) determination of the differences in the prior art and the claims in the patent applica-
tion; (3) determination of the level ordinary skill in the art; and (4) secondary considera-
tions such as commercial success. 114 These determinations must be based on information
available at the time the invention was made.15 In addition, the prior art must suggest or
motivate a change in the prior art to render the invention at issue obvious. 116 The general
test for obviousness has been described as "whether an average person who works in the
particular field would deduce, realize, or discover the invention from information in the
public domain' 117
The determination of the level of skill of the average person working in the particular
field is made using several factors. 118 Some of these factors include: "(1) the educational
level of the inventor; (2) the type of problems encountered in the art; (3) the prior art solu-
tions to those problems; (4) the speed with which the innovations are made; (5) the sophisti-
cation of the technology; and (6) the educational level of active workers in the field!' 119
109. Merges, supra note 62, at 379. Nonobviousness attempts to measure the technical accomplish-
ment of the invention. Id.
110. BURCHFIEL, supra note 67, at 78. "ITihe statutory obviousness standard reflects more than a hun-
dred years of shifting precedent defining the minimum quantum of creativity which must distin-
guish a patentable invention from prior knowledge of those most familiar with the technical field
of endeavor." Id.
111. Shawn P. Foley, Nonobviousness, in THE LAW AND STRATEGY OF BIOTECHNOLOGY PATENTS, supra
note 15, at 93-94. The PTO may be applying a stricter standard for inventiveness for biotechnolo-
gy inventions because more biotechnology based patents are rejected than those based on other
technologies. i
112. Id.
113. Graham v. John Deere Co., 383 U.S. 1, 15 (1966)(citing Cuno Corp. v. Automatic Devices Corp.,
314 U.S. 84 (1941)).
114. Id. at 17. The fourth element is also called objective evidence of nonobviousness. Foley, supra
note 111, at 94; Varma, supra note 50, at 66.
115. 35 U.S.C. § 103(a).
116. BURCHFIEL, supra note 67, at 79 (citing Uniroyal, Inc. v. Rudkin-Wiley Corp., 837 F.2d 1044, 1051
(Fed. Cir.) cert-denied 488 U.S. 825 (1988)).
117. Boulware, supra note 5, at 467.
118. Foley, supra note 111, at 96.
119. Id. (citing Orthopedic Equipment Co., Inc. v. All Orthopedic Appliances, Inc., 707 F.2d 1376
(Fed. Cir. 1983)).
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In determining whether an invention is obvious, the PTO employs a procedural tool,
the prima facie case of obviousness. 120 The concept of prima facie obviousness is predi-
cated on the "assumption that chemical compounds having similar structures will have
similar properties:' 12 1 Once a patent is filed, it is presumed patentable unless the PTO can
establish a case of prima facie obviousness or otherwise defeat the claims of the patent. 122
The requirements for a prima fade case of obviousness are:
1. The prior art must disclose or suggest the modification in the
prior art process that is required for the invention, without
reference to the applicant's specification.
2. The references must convey to one skilled in the art that
there is a reasonable expectation of success if the modification is made.
3. The reference must provide detailed enabling methodology for practicing
the claimed invention.123
With the recent amendments to section 103, a biological process patent is novel and
non-obvious if: "1) the product and the process claims are in the same application and
have the same filing date; and 2) the product and the process claims were owned by the
same person when invented. ' 124 The amendment was intended to overrule Durden,125
which provided the foundation for the PTO's position that when "a genetically engineered
cell has been 'programmed' to make a known protein, use of the cell to manufacture the
protein by fermentation would be obvious."126 The effect of Durden was a massive rejec-
tion of biotechnology process claims.127 The amendment has the potential for producing a
class of very broad biotechnology patents that may be may be removed from ordinary
statutory scrutiny. 128
The suggestion has recently been made that "[tihe current state of biotechnology
DNA patent case law has shifted the balance undesirably in favor of the patent applicant by
applying ill-fitting and inapplicable traditional chemical patent law doctrines. '1 29 The use
of chemical patent law or structural similarity may not be useful in determining obvious-
ness in complex molecules such as DNA and proteins.130 Biotechnology can alter proteins
and genes in numerous ways, resulting in a product that although structurally similar, may
have unique biological properties. 131 In an attempt to create parity between biotechnology
patents and the public benefit, Varma and Abraham suggest a variation on the test for
120. Varma, supra note 50, at 66.
121. BURCHFIEL, supra note 67, at 91.
122. Varma, supra note 50, at 66.
123. BURCHFIEL, supra note 67, at 107.
124. Butterfield supra note 93, at 270. Pub.L. No. 104-41 amended § 103(b) in 1995. Id. at 269.
125. In re Durden, 763 F.2d 1406 (Fed. Cir. 1985). The court held that even if the starting material or
product nonobvious, the steps of the chemical process may be obvious. Butterfield, supra note
93, at 268.
126. Butterfield, supra note 93, at 268.
127. BURCHFIEL, supra note 67, at 131. Process patents or claims are very important to biotechnology
because the invention usually includes the process for producing the desired product. Id. at 130.
128. BURCHFIEL, supra note 67, at 133.
129. Varma, supra note 50, at 85.
130. BURCHFIEL, supra note 67, at 117.
131. Id.
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obviousness. 132 Their "suggestion test" imposes the certain criteria on the prior art; the
prior art must
(1) suggest the claimed subject matter to a person of ordinary
skill in the art; and to
(2) demonstrate a reasonable expectation of success by:
(a) providing specific guidance as to how to modify
the teachings of the prior art to arrive at the
claimed invention; and
(b) providing evidence that the suggested modification
would be successful. 133
Although the authors suggest this test may raise controversy in the biotechnology indus-
try, they emphasize any test for prima fade obviousness can be overcome by objective evi-
dence. 134 The application of their test would significantly reduce the number of patents
issued for genetic sequences. 135 Whether the PTO will employ such a test remains to be seen.
III. NAFTA Patent Provisions.
A. SCOPE OF PROTECTION.
Article 1701 requires the signatory Parties to conform to a prescribed level of protec-
tion for intellectual property rights. 136 Specifically, the NAFTA provides that "[elach Party
shall provide in its territory to the nationals of another Party adequate and effective pro-
tection and enforcement of intellectual property rights, while ensuring that measures to
enforce intellectual property rights do not themselves become barriers to legitimate
trade.'' 137 The enforcement of these rights has been a source of contention, and may con-
tinue to cause difficulties in the future. 138 Although a Party may implement more strin-
gent protection under its domestic laws than that contained in the NAFTA, 139 the Parties
must adhere to several existing international agreements for the protection of intellectual
132. Varma, supra note 50, at 81.
133. Id.
134. Id.
135. Id. at 82-84. In applying their test, the authors conclude that several patents issued for genetic
sequences would have been rendered obvious, thereby excluding them from patentability. Id.
136. NAFTA, supra note 2, art. 1701.
137. Id.
138. Zagaris, supra note 14, at 123.
139. NAFTA, supra note 2, art. 1702. Increased protection of intellectual property rights must be con-
sistent with the NAFTA. Id. However, one commentator points out that "domestic protection of
intellectual property is directly tied to the quality of international intellectual property protec-
tion." Lehman, supra note 1, at 11-12.
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property.140 The NAFTA further provides that if a Party has not acceded to the stipulated
international agreements, that Party must make every effort to do So. 141
B. REQUIREMENTS FOR PATENTABILITY:PATENTABILITY: ARTICLE 1709(1).
Article 1709(1) defines which inventions are eligible for a patent.142 The necessary
requirements each invention must possess to successfully receive a patent under the
NAFTA reflect the requirements under the laws of the member countries. 143 Specifically,
the NAFTA provides a patent must be available for "any inventions, whether products or
processes, in all fields of technology, provided that such inventions are new, result from an
inventive step and are capable of industrial application."'4 4 To harmonize this language
with U.S. law, the terms "inventive step" and "capable of industrial application" are defined
in the NAFTA as synonymous with the terms "non-obvious" and "useful," respectively. 145
In addition to delineating those inventions subject to a patent, the NAFTA also specifically
excludes certain inventions from becoming patented. 146
C. EXCLUSIONS FROM PATENTABILITY.
1. Article 1709(2): Ordre Public and Morality Exclusions.
Some of the most controversial sections regardirg intellectual property protection
under the NAFTA concern the exclusion of certain inventions from patentability. 14 7
Under Article 1709(2), a Party may exclude from patentability inventions to protect the
"ordre public or morality."14 8 These terms are not explicitly defined, 14 9 however because
these terms are not specifically defined, they are subject to interpretation by each Party and
140. NAFTA, supra note 2, art. 1701(2). Specifically, a party must, at a minimum, give effect to the
substantive provisions of: "(a) the Geneva Convention for the Protection of Producers of
Phonograms Against Unauthorized Duplication of their Phonograms, 1971 (Geneva
Convention); (b) the Berne Convention for the Protection of Literary and Artistic Works, 1971
(Berne Convention); (c) the Paris Convention for the Protection of Industrial Property, 1967
(Paris Convention); and (d) the International Convention for the Protection of New Varieties of
Plants, 1978 (UPOV Convention), or the International Convention for the Protection of New
Varieties of Plants, 1991 (UPOV Convention)". 16L
141. Id.
142. See NAFTA, supra note 2, art. 1709(1).
143. RICHARD E. NEFF & FRAN SMALLSON, NAFTA: PROTECTING AND ENFORCING INTELLECTUAL PROPERTY
RIGHTS IN NoRm AMERICA 70 & n.4 (1994).
144. NAFTA, supra note 2, art. 1709(1).
145. Id. Compare with 35 U.S.C. § 101 (1994) which provides, "fw]hoever invents or discovers any
new and useful process, machine, manufacture, or composition of matter, or any new and useful
improvement thereof, may obtain a patent therefor, subject to the conditions and requirements
of this title." Sections 102 103 additionally require that the invention be novel and nonobvious,
respectively. See 35 U.S.C.§§ 102-03 (1994).
146. NAFTA, supra note 2, art. 1709(2)-(3).
147. NEFF, supra note 143, at 70.
148. NAFTA, supra note 2, art. 1709(2).
149. See id.
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may lead to the exclusion of inventions that are politically sensitive.150
Article 1709(2) does provide limited guidance in interpreting "ordre public" by listing
some instances in which the exclusion may be invoked. 15 1 For example, a Party may
exclude an invention from patent protection to "protect human, animal or plant life or
health or to avoid serious prejudice to nature or the environment.. 152 The only appar-
ent limitation on this exclusion is that a Party may not exclude an invention from patent
protection solely on the grounds the particular subject matter of the invention in question
is one the excluding Party specifically prevents commercial exploitation of in its territo-
ry.153 Commercial exploitation by definition includes the sale of a product; therefore, a
member country cannot exclude patent protection of a product simply because it is not
legally for sale in that country.154 Despite this limitation, some commentators have assert-
ed that the ordre public and morality exclusions create a large loophole by which parties
may maintain barriers to trade specifically in the pharmaceutical industry.155
2. Exclusions under Article 1709(3).
Additional exclusions from patentability are detailed in Article 1709(3).156 Under
this section, a Party may deny patent protection to the following: "(a) diagnostic, thera-
peutic and surgical methods for the treatment of humans or animals; (b) plants and ani-
mals other than microorganisms; and (c) essentially biological processes for the produc-
tion of plants or animals, other than non-biological and microbiological processes for
such production." 157
The language of the exclusions under Article 1709(3) provides for a broad range of
exclusions. 158 Because medical devices and diagnostic devices are patentable in the United
States, there was initial concern devices already patented in the United States would not
receive patent protection in Mexico and Canada if this exclusion was invoked. 159
Moreover, the exclusions of Article 1709(3)(b) and (c) encompass many biotechnology
inventions and could prove to be problematic until the patent laws of each Party are com-
150. NEFF, supra note 143, at 71, n.7, citing reports indicating the use of the ordre public exclusion
could be used to prevent patentability of inventions ordinarily patentable in the United States.
151. NAFTA, supra note 2, art. 1709(2).
152. Id.
153. Id.
154. NEFF, supra note 143, at 71. One negotiator said "there is no poor taste exception," meaning that
simply because a Party does not approve of a product and therefore prohibits the sale of the
product based on that subjective dislike, the Party cannot invoke the ordre public exclusion to
deny that product patent protection. Id. Moreover, the author concludes there must be "a specif-
ic finding that the particular product or process would endanger life or health or would seriously
prejudice the environment." Id
155. Peggy E. Chaudhry & Michael G. Walsh, Intellectual Property Rights: Changing Levels of Protection
Under Gatt, NAFTA and the EU, 30 COLUM. J. WORLD Bus. 80, 83 (1995). The authors conclude
the pharmaceutical industry will be particularly affected by this exclusion because it is strictly
regulated in many countries. Id.
156. NAFTA, supra note 2, art. 1709(3).
157. Id.
158. NEFF, supra note 143, at 72.
159. Id. at 73.
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pletely harmonized. 160 Specifically, "Mexico does not currently [in 1994] provide patent
protection for diagnostic, therapeutic, and surgical methods," and Canada's patent laws
have been interpreted as "not providing protection for methods of medical treatment."161
a. Exclusion of Plants and Animals.
The exclusion of plants and animals as patentable subject matter is also believed to
have a chilling effect on the biotechnology industry.162 As mentioned earlier, the U.S. PTO
accepts patent applications for multicellular animals as well as genetically engineered, sin-
gle-cell organisms. 163 The U.S. PTO acted in response to the U.S. Supreme Court decision
in Chakrabarty upholding the patentability of genetically engineered, single-cell organisms
not found in nature. 164 Whereas a biotech company may patent a multicellular organism
in the United States, that same invention may not receive protection in other countries. 165
b. Exclusion of Biological Processes in the Production of
Plants or Animals.
Article 1709(3)(c) also affords a Party the option to proscribe the patenting of a bio-
logical process used to produce a plant or animal. As with the other exclusions, this exclu-
sion has a potentially broad scope and could be applicable to any biological process used in
the production of any plant or animal.166 Although non-biological processes resulting in
the production of plants or animals may be patented, 167 the biological processes of pro-
duction developed in biotech industries remains excludable.
160. Food and Drug Law Group, Blake, Cassels & Graydon, Developments in Canadian Law Relating to
Food, Drugs, Devices, and Cosmetics as of December 199Z 49 FOOD & DRUG L.J. 323,333 (1994).
161. NEFF, supra note 143, at 72.
162. Id. at 73.
163. Boulware, supra note 5, at 462.
164. Chakrabarty, 447 U.S. at 309-10.
165. Boulware, supra note 5, at 462. A patent was granted for the "Harvard Oncomouse," which is a
mouse genetically engineered to be susceptible to cancer.
166. NEFF, supra note 143, at 73. Conceivably, this exclusion could apply to processes utilizing natural-
ly occurring viruses for the production of new organisms via fusion of single cells. Id.
167. NAFTA, supra note 2, art. 1709(3)(c).
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D. PIPELINE PROTECTION.
When a member country has granted a patent for pharmaceuticals or agricultural
chemicals, and the subject matter of that patent is not recognized as patentable in another
member country, the member country not recognizing the subject matter of the patented
invention must provide patent protection if two conditions are met. 168 These conditions
are: (1) the product must not have been marketed in the country providing the protection;
and (2) the person seeking the protection must make a timely request. 16 9 Article 1709(4)
provides what is coined as pipeline protection.
170
E. RIGHTS OF A PATENTEE.
A patent is generally defined as a statutory right to exclude others from practicing or
making the invention disclosed in the patent specification. 17 1 The NAFTA confers similar
rights to a patentee. 17 2 Under Article 1709(5), a member country must provide a patentee
with "the right to prevent other persons from making, using or selling the subject matter
of the patent, without the patent owner's consent."
17 3
The NAFTA also distinguishes between a product patent and a process patent.
17 4
Specifically, Article 1709(5) provides the holder of a process patent the right "to prevent
other persons from using that process and from using, selling, or importing at least the prod-
uct obtained directly by that process, without the patent owner's consent" 17 5 Because patent
rights of the member countries were very similar when the NAFTA was negotiated, the
NAFTA did not dramatically change the substantive rights of the patentee; however, the
addition of future members to the NAFTA may have a conflict with this provision.
17 6
168. Id. at art. 1709(4). The text of Article 1709(4) is as follows:
If a Party has not made available product patent protection for pharmaceutical or agri-
cultural chemicals commensurate with paragraph 1: (a) as of January 1, 1992, for sub-
ject matter that relates to naturally occurring substances prepared or produced by, or
significantly derived from, microbiological processes and intended for food or medi-
cine, and (b) as of July 1, 1991, for any other subject matter, that Party shall provide to
the inventor of any such product or its assignee the means to obtain product patent
protection for such product for the unexpired term of the patent for such product
granted in another Party, as long as the product had not been marketed in the Party
providing protection under this paragraph and the person seeking such protection
makes a timely request.
Id.
169. IdM
170. Pipeline provisions are ones without which "a patentee of a drug, patentable in the United States
[for example] with a term of one year remaining on the exploitation of the drug, would not
enjoy patent protection for the final year in a country that did not recognize the patentability of
that drug." NEFF, supra note 143, at 74 & n.25.
171. Boulware, supra note 5, at 446. The specification must disclose enough information to enable
others to make and to use the invention. Whiteside, supra note 6$5, at 1022.




176. NEFF, supra note 143, at 75.
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The NAFTA also allows for the limitation of the rights of a patentee "provided that the
[limited] exceptions [to the exclusive rights] do not unreasonably conflict with a normal
exploitation of the patent and do not unreasonably prejudice the legitimate interests of the
patent owner, taking into account the legitimate interests of other persons." 177 The extent
of the possible limitations on the rights of a patentee have not been delineated, and this
concerns the industries relying on the protection of intellectual property.178 Finally, the
NAFTA provides for the alienability of rights conferred to the patentee.179
Additional sections of the NAFTA affect the rights of a patentee.180 In particular,
Article 1709(7) prevents a Party from discriminating in the providing of patent protection
with regard to: (1) the field of technology; (2) the territory of the Party where the inven-
tion was made; and (3) whether the products are imported or locally produced.18 1
Article 1709(7) was included in the NAFTA to harmonize the patent laws of the mem-
ber countries.18 2 Specifically, Canadian law dealing with compulsory licensing of pharma-
ceuticals was believed to discriminate against the pharmaceutical industry.183 Similarly,
prior to the NAFTA, U.S. law was believed to discriminate in that only inventorship within
the United States was considered in a patent application.' 8 4 Currently, U.S. patent law
does recognize inventorship in NAFTA countries for the purpose of determining the date
of invention.185
177. NAFTA, supra note 2, art. 1709(6).
178. NEFF, supra note 143, at 75.
179. NAFTA, supra note 2, art. 1709(9).
180. Id. at art. 1709(7)-(8).
181. Id. at art. 1709(7). Article 1709(7) provides '[subject to paragraphs 2 and 3, patents shall be
available and patent rights enjoyable without discrimination as to the field of technology, the ter-
ritory of the Party where the invention was made and whether products are imported or locally
produced? Id.
182. NEFF, supra note 143, at 76.
183. Id.
184. Id.
185. 35 U.S.C.A. § 104 (1984), It provides:
(A) In general.--
(1) Proceedings.--In proceedings in the Patent and Trademark Office, in
the courts, and before any other competent authority, an applicant
for a patent, or a patentee, may not establish a date of invention
by reference to knowledge or use thereof, or other activity with
respect thereto, in a foreign country other than a NAFTA country
or a WTO member country, except as provided in sections 119 and 365
of this title.
(2) Rights.--If an invention was made by a person, civil or military--
(A) while domiciled in the United States, and serving in any other
country in connection with operations by or on behalf of the
United States,
(B) while domiciled in a NAFTA country and serving in another
country in connection with operations by or on behalf of that
NAFTA country, or
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F. COMPULSORY LICENSING UNDER ARTICLE 1709(10).
Article 1709(10) provides for the use of a patent without the authorization of the
patentee. 186 The use of a patent by a government of persons authorized by a government
without the patentee's authorization is known as compulsory licensing.' 87 Compulsory
licenses are commonly granted in developing countries and are feared by developed coun-
tries.188 Although the NAFTA does allow compulsory licenses, the granting of these licens-
es is strictly limited. 189
1. Limitations on the Granting of Compulsory Licenses.
The first limitation on the granting of a compulsory license is that each grant of a
compulsory license must be decided on an individual basis. 190 By restricting the grant of a
license to review on an individual basis, the NAFTA prevents a member country from
granting a license to an entire industry.191
Additionally, the user of the compulsory license must have attempted to obtain
authorization from the patentee "on reasonable commercial terms and conditions and
such efforts have not been successful within a reasonable period of time."192 Importantly,
this section of the NAFTA does not define what a reasonable time is. 193 The requirement
(C) while domiciled in a WTO member country and serving in another
country in connection with operations by or on behalf of that
WTO member country, that person shall be entitled to the same
rights of priority in the United States with respect to such
invention as if such invention had been made in the United
States, that NAFTA country, or that WTO member country, as the
case may be.
(3) Use of information.--To the extent that any information in a NAFTA
country or a WTO member country concerning knowledge, use, or other
activity relevant to proving or disproving a date of invention has
not been made available for use in a proceeding in the Patent and
Trademark Office, a court, or any other competent authority to the
same extent as such information could be made available in the United
States, the Commissioner, court, or such other authority shall draw
appropriate inferences, or take other action permitted by statute,
rule, or regulation, in favor of the party that requested the
information in the proceeding.
Id
186. NAFTA, supra note 2, art. 1709(10).
187. NEFF, supra note 143, at 78-79.
188. Loi M. Berg, Comment, The North American Free Trade Agreement & Protection of Intellectual
Property: A Converging View, 5 J. TRANSNAT'L L. & POL'Y 99, 119 (1995).
189. NAFTA, supra note 2, art. 1709(10).
190. Id. Article 1709(10)(a) provides that "authorization of such use shall be considered on its indi-
vidual merits." Id
191. NEFF, supra note 143, at 79.
192. NAFTA, supra note 2, art. 1709(10)(b).
193. Id.
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to negotiate with the patentee for the right to use the patent prior to the granting of a
compulsory license can be waived in case of a national emergency, but the patentee must
be notified. 194
One of the most important limitations on compulsory licenses is that "the scope and
duration of such use shall be limited to the purpose for which it was authorized." 195- By
limiting the scope of the compulsory license, the exploitation of the patent by the patentee
is preserved as much as possible. 196 Additionally, the use is nonexclusive, nonassignable,
and the use of the patent must be for the domestic market.1 97
2. Reviewability of Compulsory Licenses.
The granting of a compulsory license is reviewable and can be terminated when the
reasons for granting the license are no longer present. 198 Further, the act of granting a
compulsory license and the amount of remuneration to the patentee are reviewable by the
judiciary or by an appropriate authority.199 Finally, a compulsory license cannot be grant-
ed to allow the exploitation of a different patent.2°°
G. ENFORCEMENT OF PATENT RIGHTS.
The length of protection for a patent under the NAFTA is twenty years from the date
of filing or seventeen years from the date the patent is granted. 20 1 During this time, the
patentee has the exclusive right to exclude others from using the patent. 20 2 If a patentee
194. Id. Article 1709(10)(b) provides in part:
The requirement to make such efforts may be waived by a Party in the case of national
emergency or other circumstances of extreme urgency or in cases of public non-com-
mercial use. In situations of national emergency or other circumstances of extreme
urgency, the riglt holder shall, nevertheless, be notified as soon as practicable. In
the case of public non-commercial use, where the government or contractor, without
making a patent search, knows or has demonstrable grounds to know that a valid
patent is or will be used by or for the government, the right holder shall be informed
promptly.
Id.
195. Id. at art. 1709(10)(c).
196. Id. at art. 1709(10)(h). The patentee is compensated for the compulsory license. Article
1709(10)(h) provides "the right holder shall be paid adequate remuneration in the circumstances
of each case, taking into account the economic value of the authorization.' Id.
197. NAFTA, supra note 2, art. 1709(10)(d)-(f). A compulsory license may be assignable only "with
that part of the enterprise or goodwill that enjoys such use." NAFTA, supra note 2, art.
1709(10)(e).
198. Id. at art. 1709(10)(g).
199. Id. at art. 1709(10)(i)-(j).
200. Id. at art. 1709(10)(1). This section allows the granting of a compulsory license for the exploita-
tion of a different patent, but only "as a remedy for an adjudicated violation of domestic laws
regarding anticompetitive practices." Id.
201. Id. at art. 1709(12). Parties are also permitted to extend the term of the patent to account for
delays in the approval process. Id. The current term of a patent in the United States is twenty
years from the date of filing. Uruguay Round of Multilateral Trade Negotiations of 1994, Pub. L.
No. 103-465, 108 Stat. 4809.
202. Id. at art. 1709(5).
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believes his or her patent is being infringed by someone using the patent without autho-
rization, he or she can bring legal action against the infringing Party within the term of the
patent.203
The NAFTA provides that each member must make enforcement measures available
under domestic law "so as to permit effective action to be taken against any act of infringe-
ment of intellectual property rights.. .204 These measures must be "fair and equitable,"
reasonable in cost, and timely.205 Finally, decisions of each case, both judicial and adriin-
istrative, should be in writing and should include the reasoning of the decision.20 6
Additionally, Article 1715 provides the framework for civil and administrative proce-
dures available for infringement of a patent.20 7 Among the procedures included are:
(a) defendants have the right to written notice that
is timely and contains sufficient detail, including the
basis of the claims;
(b) parties in the proceeding are allowed to be
represented by independent legal counsel;
(c) the procedures do not include imposition of overly
burdensome requirements concerning mandatory
personal appearances;
(d) all parties in a proceeding are duly entitled to
substantiate their claims and to present relevant
evidence; and
(e) the procedures include a means to identify an
protect confidential information. 20 8
To facilitate this provision, judicial authorities may: (1) order the production of evi-
dence; 20 9 (2) make preliminary and final determinations on incomplete evidence when a
party refused to cooperate; (3) order a Party in a proceeding to desist from infringe-
ment;2 10 (4) award damages;2 11 (5) award attorney's fees;212 and (6) provide compensa-
tion to a Party in which the proceeding was brought as an abuse of the enforcement mea-
sures. 213 Additionally, judicial authorities have powers to deter infringement, including
203. Id. at art. 1715.
204. Id. at art. 1714(1). These measures must be used to prevent the creation of trade barriers and
contain provisions to prevent abuse of the system. Id.
205. Specifically, NAFTA, supra note 2, art. 1714(2) provides that "[e]ach Party shall ensure that its
procedures for the enforcement of intellectual property rights are fair and equitable, are not
unnecessarily complicated or costly, and do not entail unreasonable time-limits or unwarranted
delays."
206. Id. at art. 1714(3). This provision also limits decisions to the evidence adduced at the hearing.
207. Id. at art. 1715.
208. Id. at art. 1715(1).
209. Id. at art. 1715(2)(a).
210. Id. at art. 1715(2)(c).
211. Id. at art. 1715(2)(d).
212. Id. at art. 1715(2)(e).
213. Id. at art. 1715(2)(f).
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the power to destroy infringing goods.2 14
Lastly, a Party has the option of providing criminal penalties in cases of willful
infringement on a commercial scale. 215 Importantly, the substantive provisions of each
member's intellectual property law vary.2 16 As a result, the actual enforcement, or lack of
enforcement, of these protections may become problematic in the future.2 17 A Party's
willingness to enforce the protection of intellectual property may be linked to how their
cultural, moral, and religious beliefs impact their view of intellectual property.218
IV. Developing Countries and Intellectual Property Protection.
Biotechnology has attracted the attention of developing countries because of the belief
biotechnology can quickly improve the economy and standard of living.2 19 Although devel-
oping countries stand to benefit from the advances of biotechnology, many of these coun-
tries do not provide adequate intellectual property protection necessary to facilitate the
transfer of such technology from developed countries to developing countries.220
Historically, developing countries have not recognized private property rights such as
intellectual property rights. 22 1 In contrast, developed countries such as the United States
have a long tradition of protecting private property rights. 222 Unlike many other industri-
alized nations, the United States recognized the importance of the protection of these
214. These powers are found in NAFTA, supra note 2, art. 1715(5) which provides:
judicial authorities shall have the authority to order that:
(a) goods that they have found to be infringing be, without
compensation of any sort, disposed of outside the channels of
commerce in such a manner as to avoid any injury caused to the
right holder or, unless this would be contrary to existing
constitutional requirements, destroyed; and
(b) materials and implements the predominant use of which has
been in the creation of the infringing goods be, without .
compensation of any sort, disposed of outside the channels of
commerce in such a manner as to minimize the risks of further
infringements.
215. Id. at art. 1717(3).
216. Kenneth D. Sibley, Foreign Patents, in THE LAW AND STRATEGY OF BIOTECHNOLOGY PATENTS, supra
note 15, at 188.
217. Chaudhry, supra note 155, at 91.
218. Zagaris, supra note 14, at 123.
219. Unfortunately, developing countries lack both the industrial and economic infrastructure neces-
sary to achieve this goal. Ratledge, supra note 33, at 3. "Biotechnology will not create an affluent
society but will only help an existing one to become more prosperous." Id. at 4.
220. Jozwiak, supra note 56, at 622-24 (writing that biotechnology has produced genetically-engi-
neered animals that could alleviate mass starvation and disease).
221. Amy E. Carroll, Comment, Not Always the Best Medicine: Biotechnology and the Global Impact of
U.S. Patent Law, 44 Am. U.L. REv. 2433, 2465 (1995)[hereinafter Carroll].
222. Id.
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forms of intangible property in its constitution.223 Developed countries recognize the
protective regulation of patenting provides incentives for private-sector investments in
high-tech, science-based biological technologies. 224
Developing countries, having less technology by definition, have been resigned to pur-
chasing technology from developed countries in an attempt to both reduce the disparity in
technology and to improve their economies. 225 Developed countries condition the sale of
technology on the forced improvement of the purchasing country's domestic intellectual
property law. As a result, developing countries have been hesitant to harmonize their
intellectual property laws with those of developed countries.226
In addition to the historical skepticism of private proptery rights, two lines of reasoning
have developed to explain the resistance developing countries have to adopting strong intel-
lectual property laws.227 First, developing countries are more likely to view technological
advances as public good rather than a private right 228 Arguably, this view is an alturistic one
similar to the concept that the good of the many outweighs the good of the few.229
Second, developing countries are concerned the granting of patents will increase the cost
of needed pharmaceuticals. 230 The increase in costs would adversely affect individuals who
need the product by potentially preventing impoverished patients from being able to purchase
them. 231 Additionally, domestic pharmaceutical industries would be required to purchase
licenses from the patentee at prices which could ultimately put them out of business.232
Despite the differng views regarding the protection of intellectual property between
developed and developing countries, these differences will become moot as more nations
sign on to other multilateral trade agreements including the General Agreement on Trade
and Tariffs.2 33
223. U.S. CONsT. art. I, § 8, cl. 8 commands in part to "promote the Progress of Science and the useful
Arts, by securing for limited Times to Authors and Inventoris the exclusive Right to their respec-
tive Writings and Dicoveries."
224. Harold H. Lee & Fredrick E. Tank, A Conceptual Framework for Biotechnology Assessment, in
BIOTECHNOLOGY: A HOPE OR THREAT? 17,21 (Iftikhar Ahmed ed., 1992).
225. Caroll, supra note 221, at 2466.
226. Id. Forcing developing countries to change their domestic laws is tantanmount to "technological
colonialism." Id.
227. Chaudhry, supra note 155, at 88; Caroll, supra note 221, at 2465.
228. Chaudhry, supra note 155, at 88.
229. Id. 'The idea of a better-ordered world is one in which medical discoveries will be free of all
patents and there will be no profiteering from life and death." Id. (quoting Indira Ghandi from
STRENGTHENING PROTECTION OF INTELLECTUAL PROPERTY IN DELEVELOPING COUNTRIES (1990)). But
see Ratledge, supra note 33, at 3, writing "[a]ltruistic biotechnology does not exist or if it does it
simply consumes money and does not generate it."
230. Caroll notes that providing increased patent protection would increase administrative costs,
which would be absorbed by the domestic economy. Caroll, supra note 221, at 2468. Chaudhry
quotes Jose Fernando Magalhaes, director of the Brazilian company Sinto Farms, as saying
"[p]atients in any country must have the option of buying a drug at the best possible price."
Chaudhry, supra note 155, at 88.
231. Chaudhry, supra note 155, at 88.
232. Id.
233. Id. at 91. The author points out that future problems are more likily to result from the use of the
exclusions of patentability, such as for ordre public, as loopholes. Id.
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V. Conclusion.
According to Coopers & Lybrand, the most important issue facing the pharmaceutical
and biotechnology industries is the timely development of new products.234 Obviously,
the next step would be to protect these new products. Whether this protection is a result of
free trade agreements or changes in domestic law, "protecting intellectual property from
counterfeiters amounts to protecting American economic well-being. '235
Although the NAFTA has been hailed as providing comprehensive intellectual proper-
ty protection, it has not changed substantive patent laws; rather, the NAFTA affects trade in
patented products. 236 The potential use of the exclusions from patentability for the protec-
tion of public ordre, morality, or public health has specific importance to the biotechnolo-
gy industry because many biotechnology inventions have the potential to fall within these
exclusions. 237 Negotiations for the elimination or restriction of these exclusions should be
pursued if the exclusions are frequently used to maintain barriers to free trade.
As more nations become parties to international agreements, the potential use of
these exclusions could increase if changes in domestic laws are not harmonized with those
of other members. The harmonization of domestic law with the international agreements
is generally a prerequisite to joining the agreement, 238 thereby making the use of the exclu-
sions less likely.
Significant changes have occurred in all three of the NAFTA members' domestic laws.
For example, as previously described, the United States now recognizes inventorship in
member countries. Canada has passed a law, Bill C 91, which gives brand-name drug mak-
ers twenty-year patent protection in an effort to conform its compulsory licensing system
with the NAFTA.239 In 1991 Mexico passed the Law for the Promotion and Protection of
Industrial Property which revised its laws on intellectual property in anticipation of the
NAFTA. 240 These changes suggest more are possible and are probably necessary as the
courts catch up to the ever advancing field of biotechnology.
234. Johanna Powell, Biotech Firms See Profit in Rationalization, FIN. PosT, Sept. 26 1996, at 15, avail-
able in 1996 WL 5741429.
235. Lehman, supra note 1, at 15.
236. Boulware, supra note 5, at 505.
237. See Neff, supra note 158 and accompanying text.
238. See NAFTA, supra note 137 and accompanying text.
239. Jennifer Lanthier, Trade Boards Lobby for Patent Drug Protection, FIN. POST, Mar 20 1996, at 9,
available in 1996 WL 5726576. Bill C-91 is up for parlimentary review in 1997. Id.
240. NEFF, supra note 143, at 82.
